CLINICAL STUDY ON CEFCLIDIN

We evaluated the clinical efficacy and safety of cefclidin (CFCL), a new cephalosporin, at a dose of 0.5-1.0g twice daily for 6-15 days in 15 patients with respiratory tract infections, including 9 cases of pneumonia, 1 of acute exacerbation of chronic bronchitis, 1 of lung tuberculosis with infecti...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 40; no. Supplement4; pp. 687 - 690
Main Authors Takebe, Kazuo, Masuda, Mitsuo, Murakami, Seiichi, Tomiyama, Tsukiko, Nakahata, Hisashi, Arai, Keiko, Sagara, Morio, Tamura, Toyokazu, Endo, Katsumi, Katano, Haruto
Format Journal Article
LanguageJapanese
Published Japanese Society of Chemotherapy 1992
Subjects
Cefclidin
Online AccessGet full text

Cover

More Information
Summary:We evaluated the clinical efficacy and safety of cefclidin (CFCL), a new cephalosporin, at a dose of 0.5-1.0g twice daily for 6-15 days in 15 patients with respiratory tract infections, including 9 cases of pneumonia, 1 of acute exacerbation of chronic bronchitis, 1 of lung tuberculosis with infection, 1 of bacterial pleurisy, 2 of mycoplasma pneumonia and 1 of PAP. The clinical efficacy was excellent in 4 patients, good in 7, and unknown in 4. Side effects were observed in 2 patients, one with drug fever and the other with sneezing, nasal obstruction, and a feeling of heat or redness of the face and the upper half of the body. Elevation of serum GPT was found in one case.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.40.Supplement4_687